PULMATRIX, INC. Cash and Cash Equivalents
PULMATRIX, INC. (PULM) had Cash and Cash Equivalents of $2.17 million as of 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-09-17
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $2.17M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $3.32M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $4.09M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $4.79M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $2.17M S-4/A · filed 2026-09-17 | |
| 2026-03-31 | $3.32M S-4/A · filed 2026-08-03 | |
| 2025-12-31 | $4.09M S-4/A · filed 2026-09-17 | |
| 2025-09-30 | $4.79M 10-Q · filed 2025-10-16 | |
| 2025-06-30 | $5.83M S-4/A · filed 2026-09-17 | |
| 2025-03-31 | $7.71M S-4/A · filed 2026-08-03 | |
| 2024-12-31 | $9.52M S-4/A · filed 2026-09-17 | |
| 2024-09-30 | $10.78M 10-Q · filed 2025-10-16 | |
| 2024-06-30 | $12.38M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $16.30M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $19.17M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $21.34M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $25.79M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $30.75M 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $35.63M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $40.68M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $42.91M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $47.53M 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $53.84M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $53.49M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $56.90M 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $63.45M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $31.66M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $34.51M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $27.25M 10-Q · filed 2021-08-10 | |
| 2020-03-31 | $24.40M 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $23.44M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $27.88M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $31.82M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $2.15M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $2.56M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $3.81M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $8.34M 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $1.55M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $3.55M 10-K · filed 2019-02-19 | |
| 2017-09-30 | $6.36M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $10.98M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $10.54M 10-Q · filed 2018-05-11 | |
| 2016-12-31 | $4.18M 10-Q · filed 2018-05-11 | |
| 2016-09-30 | $7.31M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $10.79M 10-Q · filed 2017-08-04 | |
| 2016-03-31 | $14.75M 10-Q · filed 2017-05-05 | |
| 2015-12-31 | $18.90M 10-K · filed 2018-03-13 | |
| 2015-09-30 | $22.03M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $25.51M 10-Q · filed 2016-08-04 | |
| 2015-03-31 | $2.75M 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $451.00K 10-K · filed 2017-03-10 | |
| 2014-09-30 | $753.00K 10-Q · filed 2015-11-12 | $12.88M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $1.51M 10-Q · filed 2015-08-14 | $14.27M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $15.57M 10-Q · filed 2014-11-13 | |
| 2013-12-31 | $1.43M 10-K · filed 2016-03-10 | |
| 2013-09-30 | $89.00K 10-Q · filed 2014-11-13 | |
| 2013-06-30 | $53.00K 10-Q · filed 2014-08-14 | |
| 2013-03-31 | $96.00K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |